Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Somatropin is a recombinant form of human growth hormone (GH) used primarily in the treatment of growth hormone deficiency, pediatric growth disorders, and certain wasting conditions. Its use in convalescence—the period of recovery after illness, surgery, or trauma—has some scientific basis, though it is not a mainstream or first-line therapy. Evidence suggests that somatropin can stimulate protein synthesis, increase lean body mass, and promote positive nitrogen balance. These effects may, in theory, facilitate recovery by counteracting the catabolic state often seen in prolonged illness or after major surgery or trauma.

Clinical studies have explored somatropin in critically ill patients and those with severe burns or trauma, with mixed results. Some trials demonstrated improved nitrogen retention and muscle mass, but these benefits have not consistently translated into improved clinical outcomes such as faster recovery or reduced morbidity. Notably, some large randomized controlled trials in the late 1990s (e.g., Takala et al., 1999, NEJM) found increased mortality in critically ill adults treated with high-dose GH, raising concerns about its safety in this population.

Thus, while the physiological rationale for somatropin in convalescence is strong and supported by some biochemical and clinical endpoints, the overall evidence is moderate and its use is limited due to safety concerns and lack of proven benefit in major clinical outcomes. Current guidelines do not recommend somatropin for routine support of convalescence except in specific, approved indications.

More about Somatropin
More about Convalescence

Other ingredients used for Convalescence

Other health conditions supported by Somatropin

Products containing Somatropin